\-\ Texto\\:\\ \ \(0\)\
\-\ tsh\\ \\ \\<0\\.01\\ uiu\\/ml\\	\\(0\\.34\\-4\\.82\\)\ \(0\)\
\-\ free\\ t4\\ \\ \\>3\\.66\\ ng\\/dl\\ \\	\\(0\\.77\\-1\\.61\\)\ \(0\)\
\-\ tsi\\ not\\ available\\,\\ but\\ reportedly\\ positive\ \(0\)\
\-\ radioactive\\ iodine\\ uptake\\ \\(raiu\\)\\ of\\ 85\\%\ \(0\)\
\-\ physical\\ examination\\ demonstrated\\ no\\ focal\\ nodularity\\,\\ and\\ only\\ mild\\ enlargement\\ of\\ a\\ non\\-tender\\ thyroid\\ gland\\.\ \(0\)\
\-\ patient\\ will\\ be\\ treated\\ with\\ 15mci\\ of\\ i\\-131\\.\ \(0\)\
\-\ homogenous\\,\\ diffusely\\ increased\\ uptake\\ within\\ the\\ thyroid\\ gland\\ \\(including\\ within\\ a\\ pyramidal\\ lobe\\)\\,\\ with\\ relatively\\ diminished\\ salivary\\ gland\\ activity\\.\ \(0\)\
\-\ 24\\ hour\\ raiu\\ \\=\\ 85\\%\ \(0\)\
\-\ graves\\'\\ disease\ \(0\)\
\-\ given\\ the\\ clinical\\ history\\ and\\ laboratory\\ data\\,\\ the\\ observed\\ 24\\ hour\\ raiu\\ and\\ scan\\,\\ are\\ consistent\\ with\\ graves\\'\\ disease\\.\ \(0\)\
\-\ 46yo\\ woman\\ with\\ family\\ history\\ of\\ graves\\'\\ disease\\,\\ and\\ recent\\ development\\ of\\ ophthalmopathy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ raiu\\:\\ 0\\.13653673127441995\ \(0\)\
\-\ graves\\:\\ 0\\.1244135470038784\ \(0\)\
\-\ \\'\\:\\ 0\\.10088794440670446\ \(0\)\
\-\ gland\\:\\ 0\\.08463648119517835\ \(0\)\
\-\ 85\\:\\ 0\\.07399173885475889\ \(0\)\
\-\ hour\\:\\ 0\\.07244005732674365\ \(0\)\
\-\ 0\\.34\\-4\\.82\\:\\ 0\\.0683373521237713\ \(0\)\
\-\ 3\\.66\\:\\ 0\\.0683373521237713\ \(0\)\
\-\ 0\\.77\\-1\\.61\\:\\ 0\\.0683373521237713\ \(0\)\
\-\ 15mci\\:\\ 0\\.06296411816594227\ \(0\)\
\-\ 46yo\\:\\ 0\\.06296411816594227\ \(0\)\
\-\ tsi\\:\\ 0\\.05982097779301076\ \(0\)\
\-\ 0\\.01\\:\\ 0\\.05444774383518173\ \(0\)\
\-\ thyroid\\:\\ 0\\.054299417750770705\ \(0\)\
\-\ uptake\\:\\ 0\\.0526354019332436\ \(0\)\
\-\ 24\\:\\ 0\\.051510960939937206\ \(0\)\
\-\ pyramidal\\:\\ 0\\.05048785527885622\ \(0\)\
\-\ ophthalmopathy\\:\\ 0\\.04845402377135629\ \(0\)\
\-\ uiu\\/ml\\:\\ 0\\.04734471490592471\ \(0\)\
\-\ radioactive\\:\\ 0\\.04637445798380064\ \(0\)\
\-\ i\\-131\\:\\ 0\\.04593136950442119\ \(0\)\
\-\ ng\\/dl\\:\\ 0\\.04473640299413236\ \(0\)\
\-\ salivary\\:\\ 0\\.04473640299413236\ \(0\)\
\-\ reportedly\\:\\ 0\\.044031195411142234\ \(0\)\
\-\ iodine\\:\\ 0\\.04171729627504924\ \(0\)\
\-\ nodularity\\:\\ 0\\.04171729627504924\ \(0\)\
\-\ homogenous\\:\\ 0\\.03936316903630333\ \(0\)\
\-\ t4\\:\\ 0\\.038828340575164176\ \(0\)\
\-\ diminished\\:\\ 0\\.036220028663371824\ \(0\)\
\-\ tsh\\:\\ 0\\.03597776088427024\ \(0\)\
\-\ data\\:\\ 0\\.03585940838713234\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.03507797661099308\ \(0\)\
\-\ \\=\\:\\ 0\\.034765775842481916\ \(0\)\
\-\ diffusely\\:\\ 0\\.03345510661733514\ \(0\)\
\-\ disease\\:\\ 0\\.032482268400365215\ \(0\)\
\-\ observed\\:\\ 0\\.03175984149357677\ \(0\)\
\-\ \\%\\:\\ 0\\.03090420206737996\ \(0\)\
\-\ development\\:\\ 0\\.028850916458602605\ \(0\)\
\-\ relatively\\:\\ 0\\.02834467538567418\ \(0\)\
\-\ free\\:\\ 0\\.027265124476112106\ \(0\)\
\-\ family\\:\\ 0\\.027149708875385353\ \(0\)\
\-\ enlargement\\:\\ 0\\.026283476019264305\ \(0\)\
\-\ \\<\\:\\ 0\\.025566399437998377\ \(0\)\
\-\ within\\:\\ 0\\.02527335516877646\ \(0\)\
\-\ activity\\:\\ 0\\.024853074641717352\ \(0\)\
\-\ laboratory\\:\\ 0\\.02441156384382997\ \(0\)\
\-\ including\\:\\ 0\\.023917973961185456\ \(0\)\
\-\ given\\:\\ 0\\.022708638701677074\ \(0\)\
\-\ \\(\\:\\ 0\\.02239881321686389\ \(0\)\
\-\ available\\:\\ 0\\.0222691399134868\ \(0\)\
\-\ recent\\:\\ 0\\.0222691399134868\ \(0\)\
\-\ \\)\\:\\ 0\\.02212519975545132\ \(0\)\
\-\ \\>\\:\\ 0\\.0220090505013067\ \(0\)\
\-\ positive\\:\\ 0\\.0214952371339854\ \(0\)\
\-\ will\\:\\ 0\\.020724659057202652\ \(0\)\
\-\ examination\\:\\ 0\\.020592426631585777\ \(0\)\
\-\ clinical\\:\\ 0\\.020382246512139567\ \(0\)\
\-\ only\\:\\ 0\\.019917919833216554\ \(0\)\
\-\ treated\\:\\ 0\\.019828301054913636\ \(0\)\
\-\ demonstrated\\:\\ 0\\.01943736420509277\ \(0\)\
\-\ focal\\:\\ 0\\.018918555070840327\ \(0\)\
\-\ scan\\:\\ 0\\.018544740003356423\ \(0\)\
\-\ history\\:\\ 0\\.018297899809412144\ \(0\)\
\-\ lobe\\:\\ 0\\.01782422750328321\ \(0\)\
\-\ mild\\:\\ 0\\.017443825224272378\ \(0\)\
\-\ physical\\:\\ 0\\.016251978833963086\ \(0\)\
\-\ consistent\\:\\ 0\\.016242622239001574\ \(0\)\
\-\ increased\\:\\ 0\\.01620530838604384\ \(0\)\
\-\ woman\\:\\ 0\\.01530157323634811\ \(0\)\
\-\ \\,\\:\\ 0\\.01468969347768226\ \(0\)\
\-\ but\\:\\ 0\\.014127932566151455\ \(0\)\
\-\ be\\:\\ 0\\.010215168398014954\ \(0\)\
\-\ not\\:\\ 0\\.009572237765441359\ \(0\)\
\-\ are\\:\\ 0\\.009030030019609316\ \(0\)\
\-\ no\\:\\ 0\\.00667010969537831\ \(0\)\
\-\ patient\\:\\ 0\\.006640247526483628\ \(0\)\
\-\ a\\:\\ 0\\.0061488341367225\ \(0\)\
\-\ and\\:\\ 0\\.005581674596347859\ \(0\)\
\-\ of\\:\\ 0\\.004515651193720481\ \(0\)\
\-\ with\\:\\ 0\\.0036280364679035578\ \(0\)\
\-\ the\\:\\ 0\\.0032150996442703674\ \(0\)\
\-\ \\.\\:\\ 0\\.0013759510115250494\ \(0\)\
